Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 31/74 ]
NASDAQ | Common Stock
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits.
The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups.
In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station.
The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers.
IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 3, 25 | 2.62 Increased by +12.93% | 2.40 Increased by +9.22% |
| Oct 31, 24 | 2.80 Increased by +10.67% | 2.68 Increased by +4.48% |
| Aug 6, 24 | 3.02 Increased by +13.11% | 2.88 Increased by +4.86% |
| May 1, 24 | 2.81 Increased by +10.20% | 2.67 Increased by +5.24% |
| Feb 5, 24 | 2.32 Increased by +13.17% | 2.12 Increased by +9.43% |
| Nov 1, 23 | 2.53 Increased by +17.67% | 2.37 Increased by +6.75% |
| Aug 1, 23 | 2.67 Increased by +71.15% | 2.47 Increased by +8.10% |
| May 2, 23 | 2.55 Increased by +12.33% | 2.42 Increased by +5.37% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 954.29 M Increased by +5.84% | 216.15 M Increased by +11.12% | Increased by +22.65% Increased by +4.98% |
| Sep 30, 24 | 975.54 M Increased by +6.56% | 232.84 M Increased by +9.71% | Increased by +23.87% Increased by +2.96% |
| Jun 30, 24 | 1.00 B Increased by +6.35% | 203.30 M Decreased by -9.34% | Increased by +20.26% Decreased by -14.75% |
| Mar 31, 24 | 964.10 M Increased by +7.10% | 235.58 M Increased by +10.06% | Increased by +24.44% Increased by +2.76% |
| Dec 31, 23 | 901.60 M Increased by +8.81% | 194.52 M Increased by +12.96% | Increased by +21.58% Increased by +3.81% |
| Sep 30, 23 | 915.53 M Increased by +8.78% | 212.23 M Increased by +17.29% | Increased by +23.18% Increased by +7.83% |
| Jun 30, 23 | 943.63 M Increased by +9.65% | 224.24 M Increased by +69.90% | Increased by +23.76% Increased by +54.94% |
| Mar 31, 23 | 900.20 M Increased by +7.61% | 214.05 M Increased by +10.36% | Increased by +23.78% Increased by +2.55% |